Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper
Por:
Bailly, S, Cartron, G, Chaganti, S, Cordoba, R, Corradini, P, Dull, J, Ferrarini, I, Osborne, W, Rosenwald, A, Sancho, JM, Tilly, H, Van den Neste, E, Viardot, A and Visco, C
Publicada:
1 oct 2022
Ahead of Print:
1 jun 2022
Resumen:
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Filiaciones:
Bailly, S:
Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium
Cartron, G:
Ctr Hosp Univ Montpellier, Dept Haematol, UMR CNRS 5535, Montpellier, France
Chaganti, S:
Queen Elizabeth Hosp, Dept Haematol, Birmingham, W Midlands, England
Cordoba, R:
Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst IIS FJD, Dept Hematol, Madrid, Spain
Corradini, P:
Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy
Dull, J:
Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
Ferrarini, I:
Univ Verona, Dept Med, Sect Hematol, Verona, Italy
Osborne, W:
Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England
Rosenwald, A:
Univ Wurzburg, Inst Pathol, Wurzburg, Germany
Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
:
ICO IJC Hosp Germans Trias & Pujol, Barcelona, Spain
Tilly, H:
Ctr Henri Becquerel, Dept Hematol, Rouen, France
Ctr Henri Becquerel, U1245, Rouen, France
Univ Rouen, Rouen, France
Van den Neste, E:
Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium
Viardot, A:
Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
Visco, C:
Univ Verona, Dept Med, Sect Hematol, Verona, Italy
Green Published
|